A Potent CDC7 Kinase Inhibitor for Anticancer Research
Discover XL413: A selective ATP-competitive inhibitor with promising anticancer properties for drug discovery.
Get a Quote & SampleProduct Core Value
![8-chloro-2-(2S)-2-pyrrolidinylbenzofuro[3,2-d]pyrimidin-4(3H)-one hydrochloride](https://www.nbinno.com/2025/webimg/gemini_688df8e720733_1754134759.png)
8-chloro-2-(2S)-2-pyrrolidinylbenzofuro[3,2-d]pyrimidin-4(3H)-one hydrochloride
This compound, known as XL413, is a highly potent and selective ATP-competitive inhibitor of Cdc7 kinase, demonstrating significant potential in anticancer research and drug development.
- Learn about the potent CDC7 kinase inhibitor properties of XL413 and its applications in medicinal chemistry research.
- Explore the advantages of using this selective ATP-competitive inhibitor in drug discovery programs.
- Understand the anticancer properties and antineoplastic agent role of this compound.
- Investigate its potential as a drug discovery candidate with good in vivo pharmacokinetic profiles.
Key Advantages
Potency and Selectivity
XL413 acts as a potent CDC7 kinase inhibitor, showcasing high selectivity for its target, which is crucial for minimizing off-target effects in drug development.
Anticancer Potential
With its strong anticancer properties and role as an antineoplastic agent, this compound offers a promising avenue for developing new cancer treatments.
Drug Discovery Utility
Its status as a drug discovery candidate with favorable pharmacokinetic properties makes it valuable for medicinal chemistry research and advancing new therapies.
Key Applications
Anticancer Research
Investigating the role of XL413 in targeting cancer cells and its potential for inhibiting tumor growth in preclinical models through potent CDC7 kinase inhibition.
Medicinal Chemistry
Utilizing this compound in medicinal chemistry research to understand kinase inhibition mechanisms and explore structure-activity relationships for novel drug design.
Drug Development
Advancing XL413 through drug development pipelines, leveraging its status as a potential therapeutic agent with promising in vivo tumor growth inhibition capabilities.
Biochemical Assays
Employing XL413 as a standard in biochemical assays for screening and validating other kinase inhibitors, particularly those targeting CDC7.